These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 34682788)

  • 1. Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy.
    Tomita Y; Lee D; Tsubota K; Negishi K; Kurihara T
    J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation.
    Royle P; Mistry H; Auguste P; Shyangdan D; Freeman K; Lois N; Waugh N
    Health Technol Assess; 2015 Jul; 19(51):v-xxviii, 1-247. PubMed ID: 26173799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Evolving Treatment of Diabetic Retinopathy.
    Mansour SE; Browning DJ; Wong K; Flynn HW; Bhavsar AR
    Clin Ophthalmol; 2020; 14():653-678. PubMed ID: 32184554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature.
    Chatziralli I; Loewenstein A
    Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452097
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetic Retinopathy: An Overview of Treatments.
    Mounirou BAM; Adam ND; Yakoura AKH; Aminou MSM; Liu YT; Tan LY
    Indian J Endocrinol Metab; 2022; 26(2):111-118. PubMed ID: 35873941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving strategies in the management of diabetic retinopathy.
    Abu El-Asrar AM
    Middle East Afr J Ophthalmol; 2013; 20(4):273-82. PubMed ID: 24339676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy.
    Arrigo A; Aragona E; Bandello F
    Ann Med; 2022 Dec; 54(1):1089-1111. PubMed ID: 35451900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laser Treatment Modalities for Diabetic Retinopathy.
    Pande GS; Tidake P
    Cureus; 2022 Oct; 14(10):e30024. PubMed ID: 36348830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-Based Treatment of Diabetic Retinopathy.
    El Rami H; Barham R; Sun JK; Silva PS
    Semin Ophthalmol; 2017; 32(1):67-74. PubMed ID: 27700224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy.
    Bahr TA; Bakri SJ
    Life (Basel); 2023 Apr; 13(5):. PubMed ID: 37240743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Paradigm Shift in the Management Approaches of Proliferative Diabetic Retinopathy: Role of Anti-VEGF Therapy.
    Raman R; Ramasamy K; Shah U
    Clin Ophthalmol; 2022; 16():3005-3017. PubMed ID: 36106093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical Innovations in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy.
    Berrocal MH; Acaba LA; Chenworth ML
    Curr Diab Rep; 2019 Sep; 19(10):106. PubMed ID: 31529405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diabetic retinopathy].
    Barth T; Helbig H
    Klin Monbl Augenheilkd; 2021 Oct; 238(10):1143-1159. PubMed ID: 34380155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subthreshold Micropulse Laser for Diabetic Macular Edema: A Review.
    Sabal B; Teper S; Wylęgała E
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36615074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and Future Pharmacologic Therapies for Diabetic Retinopathy.
    Villegas VM; Schwartz SG
    Curr Pharm Des; 2018; 24(41):4903-4910. PubMed ID: 30706803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor therapy for diabetic macular edema.
    Boyer DS; Hopkins JJ; Sorof J; Ehrlich JS
    Ther Adv Endocrinol Metab; 2013 Dec; 4(6):151-69. PubMed ID: 24324855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARα Agonist Oral Therapy in Diabetic Retinopathy.
    Tomita Y; Lee D; Tsubota K; Kurihara T
    Biomedicines; 2020 Oct; 8(10):. PubMed ID: 33086679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy.
    Zhao Y; Singh RP
    Drugs Context; 2018; 7():212532. PubMed ID: 30181760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal Bevacizumab (Avastin(®)) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture.
    Arevalo JF; Sanchez JG; Lasave AF; Wu L; Maia M; Bonafonte S; Brito M; Alezzandrini AA; Restrepo N; Berrocal MH; Saravia M; Farah ME; Fromow-Guerra J; Morales-Canton V;
    Curr Diabetes Rev; 2010 Sep; 6(5):313-22. PubMed ID: 20594160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.